AI Ultrasound Hits the ER: RIVANNA Secures FDA Nod for BoneEnhance

CHARLOTTESVILLE, VA – October 22, 2026 — Anyone who has spent time in an emergency department waiting room understands the bottleneck of triage. A suspected sprained ankle or fractured wrist often means hours of waiting for a conventional X-ray, occupying valuable bed space and straining clinical resources. However, the intersection of artificial intelligence and point-of-care ultrasound is rapidly creating structural solutions to these everyday community healthcare challenges.

Today, medical technology developer RIVANNA announced a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for BoneEnhance, a machine learning software module designed for the company's Accuro XV diagnostic ultrasound system. By automatically segmenting bone and surrounding tissues and enabling three-dimensional visualization of skeletal anatomy, this clearance transitions the platform from simply acquiring images to actively assisting in their interpretation.

For those of us observing the evolution of institutional innovation, this is more than a technical upgrade. It represents a fundamental shift in how frontline medical workers might soon process low-acuity trauma, potentially democratizing access to rapid, radiation-free diagnostic insights right at the point of care.

From Acquisition to Diagnosis: The Step-by-Step AI Playbook

Building an artificial intelligence tool that clinicians can trust with diagnostic decisions cannot happen overnight. It requires a deliberate, modular regulatory strategy. RIVANNA has executed this playbook with precision.

In April 2026, the company secured its initial clearance for the Accuro XV system, validating its ability to perform automated volumetric B-mode imaging using a highly specialized, conformable three-dimensional probe. That first step solved the acquisition problem, ensuring that even users with minimal training could capture a large field-of-view image simply by positioning the device.

BoneEnhance represents the critical second layer: comprehension. Each time the Accuro XV automates an image acquisition, it generates a dense volumetric dataset. The newly cleared machine learning module steps in to identify the bone and surrounding tissues within that volume. It then applies intuitive, color-coded overlays onto the two-dimensional B-mode slices, leaving the original anatomical data completely unaltered beneath the highlights. A 3D indicator maps the exact orientation of the scan, giving the reviewer spatial context.

"We founded RIVANNA to solve a problem that cuts across care settings: decision-critical information sits outside the point-of-care workflow," said Will Mauldin, PhD, Co-founder and CEO of RIVANNA, in the company's press release. "BoneEnhance is where the stack begins to close that gap for musculoskeletal care: automated volumetric acquisition, now paired with cleared software-assisted review. This clearance is the foundation: the first machine learning layer, anchoring the decision-support capabilities now in development."

To secure this clearance, the technology was subjected to rigorous validation. Across an independent five-site test set involving 233 volumes, 69,900 images, and 173 subjects, BoneEnhance achieved anatomical labeling accuracy ranging from 95.1% to 100.0%, as evaluated by three board-certified radiologists. Crucially, none of the test data had been used to train the algorithm, ensuring the system's performance holds up in real-world, unseen scenarios.

Federal Muscle: Fueling Mass-Casualty Triage Tech

Behind this commercial milestone lies a broader public health mandate. The development of this platform has been supported by federal funding from the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA).

Why is the federal government investing in point-of-care ultrasound? The answer lies in emergency preparedness. BARDA's mission includes developing medical countermeasures for mass-casualty events, chemical threats, and scenarios where traditional medical infrastructure is degraded or destroyed. In a disaster scenario, conventional radiology suites may be inaccessible or overwhelmed. A portable, cart-based system that can provide triage-grade skeletal assessments without ionizing radiation becomes an invaluable asset.

"None of it happens without BARDA's sustained support, which allowed us to do this the right way: rigorous, multi-site, and independent," noted Delphine Le Roux, PhD, PMP, Senior Director of Market Access and Strategic Partnerships at RIVANNA.

The true value of this federal investment shines through in the platform's accessibility. A recent peer-reviewed study published in the Journal of Emergency Medicine demonstrated that operators with merely one hour of hands-on training could acquire wrist and ankle images rated adequate for diagnostic interpretation in over 90% of scans. Their image quality was comparable to those acquired by seasoned emergency physicians. By decoupling the acquisition of complex imaging from the need for highly specialized operators, the technology effectively expands the capacity of any medical response team.

Unclogging the ER: Displacing the Conventional X-Ray

While mass-casualty preparedness is the ultimate backstop, the immediate battlefield for this technology is the everyday emergency department. The point-of-care ultrasound (POCUS) market is already fiercely competitive, populated by agile innovators like Butterfly Network, Exo Imaging, and legacy giants like GE HealthCare. However, many of these competitors have focused heavily on extreme portability—creating single-probe, smartphone-connected devices optimized for a wide array of general applications.

RIVANNA has carved out a distinct niche by leaning into purpose-built hardware for a specific workflow bottleneck: extremity trauma triage.

The clinical reality is that emergency rooms are drowning in low-acuity extremity injuries. If a triage nurse or advanced practice provider can reliably use AI-augmented ultrasound to assess bone integrity at the front door, it could theoretically eliminate a massive volume of conventional X-ray referrals. This would free up radiology resources for complex cases and drastically reduce patient wait times.

However, shifting this paradigm requires overcoming entrenched clinical skepticism. Radiologists and emergency physicians are trained to view the conventional X-ray as the gold standard for bone integrity. Ultrasound inherently struggles to visualize deep bone structures or subtle cortical breaches that a radiograph might easily catch.

"If a triage nurse can rule out a significant fracture at the door without waiting two hours for radiology, that completely rewrites our operational playbook," noted one emergency department medical director familiar with the evolving POCUS landscape. "But the AI has to be bulletproof. We cannot afford false negatives when a patient is sent home, only to discover a complex fracture days later. The technology has to prove it knows its own limitations."

The Road Ahead: Building the Fracture-Care Layer

This is why RIVANNA's modular strategy is so vital. By securing clearance for anatomical segmentation first, the company is building foundational trust with clinicians. The system isn't making a diagnosis yet; it is simply acting as a highly accurate anatomical guide.

The next step, however, is diagnostic. The company is actively developing an investigational musculoskeletal injury detection module (CADe/x). Where BoneEnhance labels the anatomy, this upcoming module is being trained to actively assist clinicians in evaluating potential extremity fractures and annotating soft-tissue signs associated with injury.

To fuel this next leap, the nationwide clinical study that trained BoneEnhance has been expanded from eight to ten academic medical centers. Because the data infrastructure and clinical partnerships were established during the first phase, each subsequent AI module can be developed with increasing efficiency, maximizing the return on BARDA's initial investment.

Ultimately, the clearance of BoneEnhance is a testament to what happens when institutional funding meets targeted, community-focused innovation. By addressing the "why" behind emergency room delays—the reliance on centralized, scarce diagnostic resources—technologies like this offer a blueprint for a more connected, resilient, and equitable healthcare system. The execution engine has been built, the first AI layer is cleared, and the pathway toward automated, point-of-care fracture triage is now firmly in motion.